TFC-003
Phase 3Fixed-dose triple-combination glaucoma eye drop in Phase 3.
FROM PUBLIC EVENTS · 2026-11-15
Late clinical · capacity Raising output substantially with a new eye-drop building at its Ansan plant.
Roles often seen at this stageManufacturing & MSAT · Quality QA & QC · Clinical & PV
A prescription-drug maker centred on ophthalmic medicines such as eye drops, developing a combination glaucoma eye drop.
Fixed-dose triple-combination glaucoma eye drop in Phase 3.
Retinal-disease treatment whose sales passed about KRW 14 billion within a year of launch.
Decided to invest KRW 55.5 billion in a new eye-drop building at its Ansan plant, raising eye-drop output by 133%.
Official role guide
Observed 2026-11-15
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.